Get the Stockscreener App
10.66
0.74%
-0.08
After Hours:
10.76
0.10
+0.94%
Pliant Therapeutics Inc stock is traded at $10.66, with a volume of 486.70K.
It is down -0.74% in the last 24 hours and down -16.65% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$10.74
Open:
$10.86
24h Volume:
486.70K
Relative Volume:
1.01
Market Cap:
$648.70M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-3.4498
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
-4.31%
1M Performance:
-16.65%
6M Performance:
-23.58%
1Y Performance:
-42.28%
1-Day Range:
$10.58
$11.06
1-Week Range:
$10.58
$11.40
52-Week Range:
$10.22
$18.80
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
10.66 | 648.70M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
(PLRX) Proactive Strategies - Stock Traders Daily
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Pliant Therapeutics' chief human resource officer sells $41,892 in stock By Investing.com - Investing.com South Africa
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Insider Sells $178,483.20 in Stock - MarketBeat
Bernard Coulie Sells 52,419 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 13,270 Shares - MarketBeat
Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN
Pliant Therapeutics chief business officer Hull sells $178,500 in stock By Investing.com - Investing.com Australia
Brokers Issue Forecasts for PLRX FY2025 Earnings - Defense World
Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 - MSN
Pliant Therapeutics CFO sells $225,679 in stock By Investing.com - Investing.com Canada
Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 By Investing.com - Investing.com South Africa
Pliant Therapeutics CFO sells $225,679 in stock - MSN
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock - MSN
Pliant Therapeutics chief business officer Hull sells $178,500 in stock - Investing.com India
Pliant Therapeutics' chief medical officer sells $206,973 in stock By Investing.com - Investing.com South Africa
Pliant Therapeutics' chief medical officer sells $206,973 in stock - Investing.com
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock By Investing.com - Investing.com UK
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pliant Therapeutics Grants 275,000 Stock Options to New Chief Technical Officer - StockTitan
Pliant Therapeutics appoints new Chief Technical Officer By Investing.com - Investing.com Australia
Pliant Therapeutics appoints new Chief Technical Officer - Investing.com
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer - GlobeNewswire
Pliant Therapeutics Strengthens Leadership Team with Veteran CTO Appointment for Commercial Push - StockTitan
Cantor Fitzgerald Forecasts PLRX FY2025 Earnings - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis - Defense World
PLRX (Pliant Therapeutics) 3-Year EPS without NRI Growth Ra - GuruFocus.com
PLRX (Pliant Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.2%Here's Why - MarketBeat
Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 11%Still a Buy? - MarketBeat
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Pliant Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Position Boosted by Geode Capital Management LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.9%Time to Sell? - MarketBeat
Contrasting Pliant Therapeutics (NASDAQ:PLRX) & Bionomics (NASDAQ:BNOX) - Defense World
When (PLRX) Moves Investors should Listen - Stock Traders Daily
State Street Corp Raises Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts - MarketBeat
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 3.6%Should You Buy? - MarketBeat
The Manufacturers Life Insurance Company Cuts Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
(PLRX) Trading Signals - Stock Traders Daily
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):